[EN] PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE<br/>[FR] SELS PHARMACEUTIQUEMENT ACCEPTABLES DE 2-{4-[(35)-PIPÉRIDIN-3-YL]PHÉNYL)-2H-INDAZOLE-7-CARBOXAMIDE
申请人:MERCK SHARP & DOHME
公开号:WO2009087381A1
公开(公告)日:2009-07-16
The present invention relates to pharmaceutically acceptable salts of an amide substituted indazole which are inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), previously known as poly(ADP-ribose)synthase and poly(ADP-ribosyl)transferase. The compounds of the present invention are useful as mono-therapies in tumors with specific defects in DNA-repair pathways and as enhancers of certain DNA -damaging agents such as anticancer agents and radiotherapy. Further, the compounds of the present invention are useful for reducing cell necrosis (in stroke and myocardial infarction), down regulating inflammation and tissue injury, treating retroviral infections and protecting against the toxicity of chemotherapy.
本发明涉及一种酰胺取代吲唑的药用可接受盐,它们是酶聚(ADP-核糖)聚合酶(PARP)的抑制剂,此前被称为聚(ADP-核糖)合酶和聚(ADP-核糖)转移酶。本发明的化合物可用作特定DNA修复途径缺陷肿瘤的单独治疗,以及作为某些DNA损伤剂(如抗癌剂和放疗)的增效剂。此外,本发明的化合物可用于减少细胞坏死(在中风和心肌梗死中)、下调炎症和组织损伤、治疗逆转录病毒感染以及保护免受化疗毒性的影响。